Investment Thesis
Ardent Health demonstrates solid financial health with strong liquidity metrics and reasonable leverage, but profitability growth is stalling with net income flat YoY despite 6% revenue growth. The deteriorating EPS (-39.2% YoY) combined with modest net margins (2.1%) and operating margins (4.5%) suggest operational efficiency challenges in a capital-intensive healthcare sector.
ARDT Strengths
- Strong liquidity position with 1.97x current ratio and 1.85x quick ratio, providing operational flexibility
- Healthy free cash flow generation of $470.5M (7.4% FCF margin) supporting debt service and potential reinvestment
- Conservative leverage at 0.87x Debt/Equity with $709.6M cash position reducing refinancing risk
- Consistent revenue growth of 6.0% YoY in competitive healthcare market
ARDT Risks
- Profitability deterioration with flat net income YoY and sharply declining diluted EPS (-39.2%), indicating margin compression or share dilution issues
- Thin net margins of 2.1% and operating margins of 4.5% leave minimal room for operational disruptions or cost pressures
- High capital intensity of healthcare operations with $1.1B long-term debt and relatively low ROA (2.6%) suggesting asset utilization challenges
- Significant increase in insider Form 4 filings (5 in 90 days) warrants monitoring for potential management concerns
Key Metrics to Watch
- Operating margin trend - whether margin compression reverses or continues with revenue growth
- EPS trajectory - assess if dilution is one-time or structural issue
- Return on Invested Capital - critical for capital-intensive healthcare provider
- Free cash flow sustainability - monitor if FCF can support debt reduction while funding necessary capex
ARDT Financial Metrics
ARDT Profitability Ratios
ARDT Balance Sheet & Liquidity
ARDT 5-Year Financial Trend
5-Year Trend Summary: Ardent Health, Inc.'s revenue has shown modest growth of 6% over the 5-year period. The most recent EPS of $0.43 reflects profitable operations.
ARDT Growth Metrics (YoY)
ARDT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1.4B | -$23.5M | $-0.17 |
| Q2 2025 | $1.5B | $27.0M | $0.34 |
| Q1 2025 | $1.4B | $27.0M | $0.21 |
| Q3 2024 | $1.4B | $4.1M | $0.17 |
| Q2 2024 | $1.4B | $4.1M | $0.26 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ARDT Capital Allocation
ARDT SEC Filings
Access official SEC EDGAR filings for Ardent Health, Inc. (CIK: 0001756655)